AKBA vs. MRUS, ACLX, ACAD, SWTX, RARE, AAPG, PTGX, RNA, SRRK, and MLTX
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), Avidity Biosciences (RNA), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.
Akebia Therapeutics vs. Its Competitors
Merus (NASDAQ:MRUS) and Akebia Therapeutics (NASDAQ:AKBA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.
Merus has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Akebia Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
Akebia Therapeutics has higher revenue and earnings than Merus. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.
In the previous week, Akebia Therapeutics had 7 more articles in the media than Merus. MarketBeat recorded 9 mentions for Akebia Therapeutics and 2 mentions for Merus. Akebia Therapeutics' average media sentiment score of 0.71 beat Merus' score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.
Akebia Therapeutics has a net margin of -24.51% compared to Merus' net margin of -506.73%. Akebia Therapeutics' return on equity of 0.00% beat Merus' return on equity.
96.1% of Merus shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 4.6% of Merus shares are owned by company insiders. Comparatively, 3.0% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Merus presently has a consensus target price of $84.64, indicating a potential upside of 57.20%. Akebia Therapeutics has a consensus target price of $6.75, indicating a potential upside of 87.24%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Merus.
Summary
Akebia Therapeutics beats Merus on 10 of the 17 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akebia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AKBA) was last updated on 7/3/2025 by MarketBeat.com Staff
Free AKBA Stock Alerts